GlassScriptPhysician profile
Latoya Walton-Torrence
NPI 1841295458
$4,255.00
in general payments reported to CMS, 2019-2025
29 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $168 · 2021: $281 · 2022: $457 · 2023: $368 · 2024: $282 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,009 · Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,009.00 |
| Food and Beverage | $941.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,134.79 | 2019-2025 | |
| Abbvie INC. | $580.00 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $281.50 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $232.45 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Coolseal Generator |
| Sumitomo Pharma America, INC. | $162.68 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $94.59 | 2019-2024 | |
| Millicent US INC | $85.33 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Aspira Women'S Health INC | $72.49 | 2021 | |
| Scynexis, INC. | $69.62 | 2022 | |
| Ethicon US, LLC | $64.14 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $63.36 | 2021-2022 | |
| Amgen INC. | $38.08 | 2019-2021 | |
| Shield Therapeutics INC | $36.85 | 2025 | |
| Sage Therapeutics, LLC | $35.80 | 2024-2025 | Zurzuvae |
| Organon LLC | $35.08 | 2023-2025 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.22 | 2019 | |
| Agile Therapeutics, INC. | $25.52 | 2021-2022 | |
| Therapeuticsmd, INC. | $24.40 | 2019-2020 | |
| Conmed Corporation | $23.82 | 2024 | Airseal |
| Exeltis, USA INC. | $23.08 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.77 | 2023 | Exparel |
| Coopersurgical, INC. | $18.08 | 2019 | |
| Lupin INC. | $17.07 | 2019 | |
| Roche Diagnostics Corporation | $16.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.75 | 2019 | |
| Daiichi Sankyo INC. | $13.68 | 2019 | |
| Baxter Healthcare | $13.53 | 2022 | |
| Myovant Sciences INC. | $13.01 | 2021 | |
| Avion Pharmaceuticals | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Walton-Torrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.